A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pegfilgrastim-Apgf (NYVEPRIA)

Pegfilgrastim-Apgf stimulates white blood cell production, used to prevent infections during chemotherapy.

First FDA approval2020-12-15
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$21.3M in CY2024 Part D spend5K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
94 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Pegfilgrastim-Apgf used for?

Pegfilgrastim-Apgf stimulates white blood cell production, used to prevent infections during chemotherapy.

Is there a generic for Pegfilgrastim-Apgf?

No. Pegfilgrastim-Apgf is brand-only with no generic equivalents currently in market.

How much does my plan pay for Pegfilgrastim-Apgf?

NADAC pricing data not currently available for this drug.

Is Pegfilgrastim-Apgf on the FDA shortage list?

No. Pegfilgrastim-Apgf is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Leukocyte Growth Factor1 alternative in D1
01
Pegfilgrastim
Brand: FYLNETRA
$3185.94Lowest NADAC
0Generic mfrs
$137.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.